×

Biotech and Pharmaceuticals Pharmaceuticals

  • Sales at Bayer, the German pharmaceuticals company, rose 5.4 percent to 9,252 million euro ($13,282 million) in the second quarter.

  • In the next 14 months, patents for the top 20 drugs in the U.S. are set to expire. Although makers of such top-selling drugs, such as Lipitor and Plavix, will no longer have a monopoly on these drug formulas, pharmaceutical stocks will be able to weather the loss of these patents, said two health-care analysts.

  • pharma_new2.jpg

    The chief executive and founder of Actelion, one of the world's biggest biotechnology companies, said the firm would stay independent despite pressure from activist shareholders.

  • Earnings Preview: Johnson & Johnson

    A look ahead of tomorrow's earnings and where the pharmaceutical giant is likely to find growth, with Damien Conover, Morningstar.

  • Eli Lilly: Patents, Pipeline & Growth

    Insight on the giant pharma's plans to increase R&D and roll out a raft of new meds, with John Lechleiter, Eli Lilly CEO.

  • Diamonds

    The Arab Spring helped boost diamond prices as the region's wealthy individuals moved their cash from stocks and bonds to safe haven investments and tangible assets , a London-based fund manager told CNBC Tuesday.

  • fda_medicine_200.jpg

    A panel of federal cancer experts says the best-selling cancer drug in the world should no longer be approved to treat breast cancer because it is ineffective and causes dangerous side effects.

  • Novartis

    Novartis broke ground this week for our new manufacturing plant outside St. Petersburg, Russia. The facility is part of our $500 million, five-year commitment to help improve Russia’s healthcare infrastructure. Our investment addresses local manufacturing, R&D collaborations and public health development.

  • The problems facing US healthcare have not yet been fully resolved, according to the chief executive of AstraZeneca.

  • Novartis CEO Joe Jimenez

    Novartis CEO Joe Jimenez talks to CNBC's Maria Bartiromo about opportunities in Russia, as well as the new facility the company is building there.

  • As the U.S.'s middle class withers away, the traditional defensive plays aren't working anymore.

  • Billions Under Scrutiny

    CNBC's Eamon Javers has the story on who got a multi-billion dollar, no-bid contract, and whether political influence was at play.

  • Cancer Drug Targets Tumor Cells

    Clay Siegall, Seattle Genetics CEO discussing the next generation of drugs in the battle against cancer.

  • roche_genentech.jpg

    These more targeted, or niche,  drugs might only treats thousands, but they could yield higher success rates for patients and lower marketing costs for the industry.

  • Steve Jobs

    Juxtapositions galore. Apple gets ready to debut its iCloud, while everyone else's cloud gets hacked. Portuguese elections set the stage for austerity, while austerity rocks Greece. Here's what we're watching...

  • Counterfeit goods generate hundreds of billions of dollars in sales each year, making up about 7 percent of all global trade.At US ports alone, counterfeit products seized in 2009 had an estimated street value of more than $260 million. Authorities are unsure just how many counterfeit goods enter the United States each year, but one thing is certain: Counterfeiting saps economies, puts lives in jeopardy and funds organized crime around the globe.So which counterfeit goods are seized most often?

    Counterfeit goods generate hundreds of billions of dollars in sales each year, making up about 7 percent of all global trade.

  • Dificid is the first new FDA- drug approved for the infection in nearly 25 years, according to Optimer Pharmaceuticals.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • large_syringe_200.jpg

    GlaxoSmithKline is seeing strong, double-digit growth from sales in emerging markets, offsetting sales declines from generic drugs in the U.S. and Europe, Chief Executive Andrew Witty told CNBC Tuesday.